QuidelOrtho (NASDAQ:QDEL) Posts Quarterly Earnings Results, Misses Expectations By $0.44 EPS

QuidelOrtho (NASDAQ:QDEL) announced its quarterly earnings results on Wednesday. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.07 by ($0.44), Zacks reports. QuidelOrtho had a negative net margin of 66.25% and a positive return on equity of 4.24%. QuidelOrtho updated its FY 2025 guidance to 2.070-2.570 EPS.

QuidelOrtho Trading Up 4.3 %

QDEL opened at $41.65 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.81 and a current ratio of 1.38. QuidelOrtho has a fifty-two week low of $29.74 and a fifty-two week high of $49.56. The firm’s fifty day moving average is $43.28 and its 200 day moving average is $42.35.

Insider Activity at QuidelOrtho

In related news, CEO Brian J. Blaser purchased 6,033 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were acquired at an average price of $41.42 per share, for a total transaction of $249,886.86. Following the purchase, the chief executive officer now directly owns 6,033 shares in the company, valued at $249,886.86. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $35.31, for a total transaction of $291,667,061.73. The disclosure for this sale can be found here. 1.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

QDEL has been the subject of a number of research analyst reports. Citigroup raised shares of QuidelOrtho from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $44.00 to $50.00 in a research report on Wednesday, December 11th. William Blair reaffirmed a “market perform” rating on shares of QuidelOrtho in a research report on Wednesday, November 20th. StockNews.com raised shares of QuidelOrtho from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Jefferies Financial Group initiated coverage on shares of QuidelOrtho in a research report on Tuesday, December 10th. They issued a “hold” rating and a $43.00 target price for the company. Finally, Royal Bank of Canada cut their target price on shares of QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating for the company in a research report on Thursday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $52.71.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.